Valeant Pharmaceuticals International, Inc. (T:VRX)
Business Focus: N/A
Apr 06, 2018 08:30 am ET
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis
Top line Data expected in Q3 2018
Nov 08, 2017 08:30 am ET
EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery
Triggers Milestone Payment under Global Licensing Agreement with Valeant Pharmaceuticals
Jul 14, 2017 06:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
Results of the Quarterly Review of the S&P/TSX Composite Buyback and Shareholder Yield Indices
Jul 06, 2016 01:39 am ET
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, July 6, 2016 (GLOBE NEWSWIRE) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. (Euronext Paris: COX) today announced that the results of a Phase 3 study for latanoprostene bunod (LBN) ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology. LBN 0.024% is an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily for patients with open angle glaucoma (OAG) or ocular hypertension (OHT). ...
Apr 29, 2016 10:49 am ET
IIROC Trade Resumption - VRX
TORONTO, April 29, 2016 /CNW/ - Trading resumes in:
Apr 29, 2016 10:37 am ET
IIROC Trading Halt - VRX
TORONTO, April 29, 2016 /CNW/ - The following issues have been halted by IIROC:
Mar 21, 2016 10:18 am ET
IIROC Trade Resumption - VRX
TORONTO, March 21, 2016 /CNW/ - Trading resumes in:
Mar 21, 2016 10:04 am ET
IIROC Trading Halt - VRX
TORONTO, March 21, 2016 /CNW/ - The following issues have been halted by IIROC:
Mar 21, 2016 09:25 am ET
IIROC Trade Resumption - VRX
TORONTO, March 21, 2016 /CNW/ - Trading resumes in:
Mar 11, 2016 05:15 pm ET
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
